Where is SYDRA located?

SYDRA is headquartered in Schlieren, Switzerland.

Who is the current CEO of SYDRA?

Alexander Dakhovnik of SYDRA. They have also founded 1 company.

Is SYDRA a funded company?

SYDRA is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does SYDRA rank among its competitors?

SYDRA ranks 115th amongst 167 active competitors, of which 67 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Tandem AI, which secured $22M in Nov, 2025.

Who are the top competitors of SYDRA?

SYDRA's top competitors include Schrodinger, Recursion Pharmaceuticals and XtalPi. Among them, Tandem AI secured the most recent funding round in November, 2025.

SYDRA - 2026 Company Profile, Team & Competitors

Company Details

Provider of Artificial Neural Networks and autonomous robotic technology to discover novel geroprotectors for longevity research. It has proprietary closed-loop discovery platform that enables the identification of effective treatments for age-related diseases and to identify novel small molecules with geroprotective properties.

Website: sydra.bio
Email ID: *****@sydra.bio

Key Metrics

Founded Year

2024

Location

Schlieren, Switzerland

Stage

Unfunded

Ranked

115^th among 167 active competitors

Similar Companies

Schrodinger & 196 more

View SYDRA's full profile

SYDRA has not raised any funding rounds yet.

The founders of SYDRA are Pavlo Mozharovskyi and Alexander Dakhovnik. Alexander Dakhovnik is the CEO of SYDRA.

Here are the details of SYDRA's key team members:

Pavlo Mozharovskyi: Co-Founder & CTO of SYDRA.
Contact Info: 1 email address
Alexander Dakhovnik: Co-Founder & CEO of SYDRA.
Contact Info: 1 email address

View details of SYDRA's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of SYDRA include Schrodinger, Recursion Pharmaceuticals and XtalPi. Here is the list of Top 10 competitors of SYDRA, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Schrodinger 1990, New York City (United States), Acquired	Provider of a web-based simulation and modelling tool	$162M	Gates, WuXi AppTec & 16 others	74/100
2nd	Recursion Pharmaceuticals 2013, New York (United States), Public	AI-enabled drug discovery and development platform for novel therapeutics	$452M	Baillie Gifford, Felicis Ventures & 46 others	72/100
3rd	XtalPi 2014, Cambridge (United States), Public	AI-based drug research and development company	$785M	SoftBank Vision Fund, Tencent & 25 others	67/100
4th	Xaira 2023, San Francisco (United States), Series D	AI-enabled platform for drug discovery and development	$1B	Arch Venture Partners, Foresite Labs & 11 others	63/100
5th	METiS Therapeutics 2017, Cambridge (United States), Series B	Provider of an AI-assisted platform for drug discovery and development	$252M	Sequoia Capital China, Luminous Ventures ... & 13 others	63/100
6th	Valo Health 2019, Boston (United States), Series B	AI-powered platform for drug discovery and development	$450M	PSP Investments, Koch Disruptive Technologies ... & 7 others	63/100
7th	Tandem AI 2021, New York (United States), Series A	AI-based drug discovery tool for researchers	$82M	Orbimed, Qiming Venture Partners & 4 others	63/100
8th	In Silico 2014, Cambridge (United States), Public	AI-enabled bioinformatics platform for drug discovery and biomarker development	$510M	Qiming Venture Partners, Warburg Pincus & 36 others	62/100
9th	Gero 2015, Singapore (Singapore), Series A	Developer of reverse engineering technology for controlling aging	$13.5M	Bulba Ventures, Melnichek Investments & 13 others	62/100
10th	Healx 2014, Cambridge (United Kingdom), Series C	Provider of AI-powered drug discovery solutions for rare diseases	$115M	Atomico, Balderton Capital & 18 others	62/100
115th	SYDRA 2024, Schlieren (Switzerland), Unfunded	Provider of Artificial Neural Networks and autonomous robotic technology to discover novel geroprotectors for longevity research	-	-	24/100